A monthly publication providing critical insights into the business of medical innovation in Europe. Published in London, distributed by subscription worldwide.
The Jul-Aug 2023 edition of @MedNous with articles on the new EU patent and the use of real-world evidence in regulatory decision making is now out. For further information write to [email protected].
@argenxglobal raises $1.27 bln in global offering, after exercise of underwriters' options, to support pipeline of therapies for autoimmune diseases. see @MedNous
@NodThera reports positive data from small molecule drug being tested for Parkinson's disease. In volunteers, drug reduced neuroinflammatory biomarkers. see @MedNous
Write to [email protected] for a complimentary copy of the June edition of MedNous with articles on a preclinical project for Alzheimer's disease, a review of ASCO 2023 and an exclusive report on biotech incubation in the UK.
The May issue of @MedNous is now out featuring a review of proposed EU pharma legislation, new statistics on oncology drug development timelines and an interview with the radiopharmaceutical company @Ariceum_Tx. For a complimentary copy write to [email protected].
The April edition of @MedNous is now out with articles on HIV vaccine research, the development of a new antibacterial by @destinypharma and a discussion of p38 MAPK inhibition by Matthew Wright at Kinarus. For a complimentary copy, write to [email protected].
Alentis Therapeutics completes Series C financing of $105 mln to develop anti-claudin-1 antibodies, supported by @jeito_life and @novoholdings. see @MedNous
The March edition of @MedNous is now available to subscribers. It features original research for type 2 diabetes, a review of the late-stage oncology drug pipeline and an interview with #Adrenomed on septic shock. For further information, write to [email protected].